Significant EU funding for international AICCELERATE consortium proposing a scalable AI tool for smart hospital

The AICCELERATE consortium consists of specialists in the fields of IT, machine learning, robotics, neurology, paediatrics and surgery from Finland, Italy, Spain, Turkey, Netherlands, Germany and Belgium.
Healthcare systems lack flexible AI solutions that allow hospitals to improve efficiency and the quality of patient care. Current solutions provide limited scalability and are confined to isolated applications. Scalable models that address data sharing, integration, privacy, and ethics are needed to ensure better adoption of AI in healthcare. Patient empowerment and evidence-based trust towards AI is a key part of the project. Evaluation activities will also focus on cost-benefit analysis of the AI-solutions.
AICCELERATE will develop partners’ existing digital solutions further to enable the development of a Smart Hospital Care Pathway (SHCP) Engine. This engine serves as a toolset for AI models and robotics to improve quality of care and health outcomes. It will also enable lean management and effective decision-making.
These tools are tested in three pilots that will provide feedback for improving the SHCP Engine: (i) patient flow management for ER and surgical units, (ii) digital care pathway for Parkinson’s disease, and (iii) paediatric service delivery.
The pilots are carried out by 5 hospital partners: Helsinki University Hospital and Oulu University Hospital from Finland, Ospedale Pediatrico Bambino Gesù from Italy, Barcelona Children's Hospital from Spain, and University Hospital Università degli Studi di Padova from Italy.
In addition to these above mentioned hospitals The AICCELERATE consortium is formed by Erasmus Univ. Rotterdam from Netherlands, RTO Fundació Eurecat from Spain, a Spanish non-profit TICBioMed, 6 SMEs aiming to advance the digitalization of the European healthcare services: Chino from Italy, Symptoma from Austria, Nuromedia from Germany, SRDC from Turkey, Evondos from Finland, NeuroPath from Belgium, and 2 large enterprises NEC Laboratories Europe from Germany and Innofactor from Finland. The preparation of the proposal was supported by Spinverse from Finland.
Keywords
Contacts
More information:
Development Manager Tuuli Pajunen
tuuli.pajunen@hus.fi, +358 40 182 5028
Research and Innovation Manager Suzan Ikävalko,
suzan.ikavalko@hus.fi, +358 50 583 4292
Images
About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Gips räcker vid frakturer på mediala humerusepikondylen vid armbågsleden hos barn9.9.2025 09:55:56 EEST | Pressmeddelande
I en nyligen publicerad studie framgick det att gipsning som behandling vid frakturer på mediala humerusepikondylen hos barn är en lika effektiv behandlingsform som operation. De resultat som man nu fått stöder gipsbehandling som primär behandlingsform och behandlingen kan förenhetligas på riksnivå.
Kipsi riittää lasten kyynärnivelen koukistajalisäkkeen murtumissa9.9.2025 09:55:56 EEST | Tiedote
Juuri julkaistussa tutkimuksessa selvisi, että lasten kyynärnivelen koukistajalisäkkeen murtumien hoidossa kipsaus on yhtä tehokas hoitomuoto kuin leikkaus. Nyt saadut tulokset tukevat kipsihoidon käyttöä ensisijaisena hoitomuotona, ja hoitoa voidaan yhtenäistää kansallisesti.
Den nyaste ekonomiska prognosen för hela 2025: HUS är på väg att uppnå sina ekonomiska mål för 20258.9.2025 12:09:48 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade på sitt möte verksamheten och ekonomin i januari–juli samt den nyaste årsprognosen för hela 2025. HUS-sammanslutningens operativa resultat beräknas uppvisa ett överskott på 0,1 miljoner euro. Sammanslutningens styrelse fastställde också investeringsplanen och investeringsprogrammet för de kommande åren.
Koko vuoden 2025 uusin talousennuste: HUS pääsemässä vuonna 2025 taloudellisiin tavoitteisiinsa8.9.2025 12:09:48 EEST | Tiedote
HUSin yhtymähallitus käsitteli kokouksessaan tammi–heinäkuun taloutta sekä uusinta koko vuoden 2025 vuosiennustetta. HUS-yhtymän operatiivisen tuloksen ennustetaan päätyvän 0,1 miljoonaa euroa ylijäämäiseksi. Yhtymähallitus vahvisti myös tulevien vuosien investointisuunnitelman ja -ohjelman.
Förebyggande av RS-virusinfektion hos spädbarn inleds på HUS sjukhus3.9.2025 14:17:24 EEST | Pressmeddelande
RS-virus (respiratory syncytial virus, RSV) är den vanligaste orsaken till luftvägsinfektioner som kräver sjukhusvård hos små barn. HUS erbjuder en antikropp som utvecklats mot RS-virus, det vill säga nirsevimab åt nyfödda och barn under ett år som hör till riskgrupperna.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom